Group items tagged

Researchers at the University of Oxford have received a grant of up to £600,000 from Cancer Research UK to develop the world's first vaccine to prevent ovarian cancer. Named OvarianVax, the innovative vaccine aims to train the immune system to recognise and attack the earliest stages of ovarian cancer. Ovarian cancer is the sixth most common cancer among women in the UK, with approximately 7,500 new cases diagnosed annually-equating to about 21 cases each day. It is also a leading cause of cancer-related deaths in women, with around 4,100 deaths each year, accounting for five per cent of all cancer deaths in UK females. Projections suggest that by 2038-2040, there could be around 9,400 new cases of ovarian cancer annually in the UK. Several factors influence a person's risk of developing ovarian cancer, including age, genetics, hormone replacement therapy (HRT), smoking, asbestos exposure, medical conditions such as endometriosis or diabetes, and obesity. Faults in the inherited genes, particularly BRCA1 and BRCA2, are linked to a higher risk of ovarian cancer, contributing to 5-15 per cent of cases.

In a significant move to address health disparities and enhance clinical research, community pharmacies across several regions are set to become central players in the Genes and Health study. Led by Queen Mary University of London and funded by the Wellcome Trust, this national initiative aims to improve health outcomes within British-Bangladeshi and British-Pakistani communities. Professor Mahendra Patel, Director of the Centre for Research Equity at the University of Oxford, highlighted the importance of this approach. "By engaging the broader pharmacy workforce, including technicians, we aim to establish a research-ready infrastructure within community pharmacies," Patel told Pharmacy Business. He shared that the initiative marks a transformative step in integrating pharmacies into the clinical research landscape. The Thames Valley and South Midlands Clinical Research Network (CRN) is managing a pioneering pilot program for this study, which will initially focus on pharmacies in Banbury, Oxford City, Reading, Slough, High Wycombe, and Aylesbury.

The NIHR Research Delivery Network (RDN) has published a new paper highlighting the learnings from a major COVID-19 research trial conducted in primary care settings. The paper, which draws on insights from the PANORAMIC study, emphasised the importance of prioritising primary care studies from the very start of any pandemic to prevent worsening of patient symptoms and reduce hospital admission. Additionally, it recommended considering the use of UK-wide pharmacy networks, including community pharmacies, to promote research inclusion for future similar trials in primary care to increase recruitment in underserved communities. Authored by Professor Phil Evans, GP and Deputy Health and Care Director at the NIHR RDN together with colleagues from the NIHR and University of Oxford, the 80-page paper concluded that primary care research should be at the forefront of future pandemic preparedness. During the early stages of the COVID-19 pandemic, much research was carried out on critically ill patients in secondary care settings.

In partnership with Oxford University Press, the Royal Pharmaceutical Society (RPS) has launched the 'RPS Pharmacy and Pharmacology' reports. RPS Pharmacy and Pharmacology Reports is a new, fully open access journal and the sister journal to Journal of Pharmacy & Pharmacology. The journal is edited by Professor Dennis Douroumis, professor in Pharmaceutical Technology and Process Engineering at the University of Greenwich. RPS said: "The journal aims to create a truly interdisciplinary forum for members of the pharmacy, pharmacology, chemistry, biochemistry, physiology, and microbiology communities alike to come together to develop life-changing medicines of the future. The journal prioritises scientifically sound results from pharmacy and pharmacology researchers across the world." The journal operates a rapid review and publication process to ensure impactful research is disseminated as quickly as possible. All RPS members are eligible to receive a 20 per cent discount on the article processing charge.

The University of Oxford's Centre for Research Equity (CfRE) has entered into a historic partnership with the Health and Social Care Research and Development (HSC R&D) Division in Northern Ireland to advance health equity across the region and ensure everyone benefits from healthcare advancements. Unveiled during an event at Parliament Buildings in Stormont Estate on Wednesday, this groundbreaking partnership makes Northern Ireland the first UK region to partner with CfRE. Supported by the Department of Health Northern Ireland and key health and social care agencies, the partnership aims to improve health outcomes and reduce disparities through collaborative research. Northern Ireland's Health Minister, Mike Nesbitt, highlighted that this new partnership represents "a significant step forward in efforts to address health inequalities" in the region. "By bringing together leading experts and resources from across sectors, we can work towards conducting research that truly benefits all of our communities," he said.

Researchers from the London School of Hygiene & Tropical Medicine (LSHTM) have been tasked to evaluate the impact, safety and effectiveness of the Pharmacy First service, which was launched across England in January 2024. They have been awarded £2.4million by the National Institute for Health and Care Research (NIHR) to generate evidence on the new service that allows pharmacies to provide advice and treatment for seven common conditions without the need for a GP appointment. After consultation, if necessary, a community pharmacist can supply some prescription-only medicines to treat earache, sore throat, sinusitis, impetigo, shingles, infected insect bites or uncomplicated urinary tract infections in women. The LSHTM researcher team will be working together with experts at the UK Health Security Agency (UKHSA) and the Universities of Oxford, Manchester and Nottingham on the project. Dr Rebecca Glover, assistant professor in Antimicrobial Resistance at LSHTM, who will lead the three-year project, said they will evaluate "Pharmacy First's impact on GPs and the wider NHS, pharmacy services and patients."

In a new study, men who took phosphodiesterase type 5 inhibitors (PDE5Is), such as Viagra (sildenafil; Pfizer), for treatment of erectile dysfunction, were found to be 18 per cent less likely to develop Alzheimer's compared to those who did not take the drugs. The results of the population-based cohort study were published in Neurology on 7 February 2024. Researchers at University of Oxford examined IQVIA Medical Research Data UK records of 269,725 men, who were diagnosed with erectile dysfunction between January 2000 and March 2017. None of the participants had any memory or thinking problems at the start of the study and they were followed for an average of 5.1 years. During the study, 749 out of 1,119 participants taking erectile dysfunction drugs developed Alzheimer's disease.

Professor Mahendra Patel OBE, CEO of the Oxford University Centre for Research Equity (CfRE), has been appointed as an independent expert member of the UK Pharmacy Professional Leadership Advisory Board. The newly established Board comprises nine independent expert members (IEMs) with outstanding leadership capabilities, who were appointed through open recruitment, ensuring a "broad, balanced, and diverse" representation. Sir Hugh Taylor KCB, the Independent Chair of the Board, and the UK Chief Pharmaceutical Officers (CPhOs) - Andrew Evans (Wales), Cathy Harrison (Northern Ireland), Alison Strath (Scotland), and David Webb (England) - announced the appointment of IEMs in an open letter to the UK pharmacy professions. "Bringing a wealth of experience and expertise, they will play a pivotal role in the Board's work to deliver an exciting vision through supporting a new and dynamic phase of collaboration," the CPhOs said. As the CEO of CfRE, Professor Patel spearheads efforts aimed at addressing inequalities in healthcare.

Three leading pharmacists - professor Mahendra Patel, Asif Aziz and Ade Williams - have been recognised in Queen Elizabeth's annual New Year's honours list. Professor Patel, an academic pharmacist from West Yorkshire, was awarded an OBE for his "services to pharmacy." He told Pharmacy Business: "I am truly honoured and deeply humbled by this highly prestigious award that I have always believed was more deserving for others. "That's not to say I'm not proud of it - far from it, although for me it's not necessarily about rewards and recognition but more the intricacies of the journey I embark on and the learning and joy that those encounters bring with it. Most recently, Professor Patel - who has had a broad ranging portfolio career spanning community pharmacy, health education and health promotion, academia, and research - has been involved in promoting clinical trials across community pharmacies in the UK. His latest work has seen him act as one of the national leads for the PRINCIPLE and PANORAMIC trials, run by Oxford University - both trials seek to pioneer repurposed and new drug treatments in the community to prevent hospitalisation due to Covid-19.